Zobrazeno 1 - 10
of 82
pro vyhledávání: '"David B. Geffen"'
Autor:
Merav Fraenkel, Victor Novack, Yuval Mizrakli, Michael Koretz, Ethel Siris, Larry Norton, Tali Shafat, David B. Geffen
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Estrogen may have opposing effects on health, namely increasing the risk of breast cancer and improving bone health by increasing bone mineral density (BMD). The objective of this study was to compare dual-energy X-ray absorptiometry (DXA) B
Externí odkaz:
https://doaj.org/article/187ecc44aa124835a7681919d71d48a7
Publikováno v:
BMC Bioinformatics, Vol 21, Iss 1, Pp 1-10 (2020)
Abstract Background Compared to the many uses of DNA-level testing in clinical oncology, development of RNA-based diagnostics has been more limited. An exception to this trend is the growing use of mRNA-based methods in early-stage breast cancer. Alt
Externí odkaz:
https://doaj.org/article/ba07e601464949e280f8310dfb66f92c
Autor:
Merav Fraenkel, Victor Novack, Yair Liel, Michael Koretz, Ethel Siris, Larry Norton, Tali Shafat, Shraga Shany, David B. Geffen
Publikováno v:
PLoS ONE, Vol 8, Iss 9 (2013)
Externí odkaz:
https://doaj.org/article/0fb30a6867fa420ab928e21d2ddc5be9
Autor:
Lisi M. Dredze, Michael Friger, Samuel Ariad, Michael Koretz, Bertha Delgado, Ruthy Shaco-Levy, Margarita Tokar, Michael Bayme, Ravit Agassi, Maia Rosenthal, Victor Dyomin, Olga Belochitski, Shai Libson, Tamar Mizrahi, David B. Geffen
Publikováno v:
Breast cancer research and treatment. 193(3)
We analyzed outcomes of doxorubicin-cyclophosphamide (AC) followed by weekly paclitaxel as neoadjuvant chemotherapy (NAC) for breast cancer (BC), in an everyday practice with long-term follow-up of patients.All patients (n = 200) who received the AC-
Autor:
Benjamin W. Corn, G. Fried, Roxolyana Abdah-Bortnyak, Bella Kaufman, M. Inbar, Hadassah Goldberg, Abraham Kuten, M. R. Pfeffer, Raphael Catane, Ora Rosengarten, A. M. Ben-David, David B. Geffen, P. Chernobelsky, Diana Matceyevsky, Ella Evron, T. Karni
Publikováno v:
Annals of Oncology. 30:412-417
Background Women who carry germ-line mutations in BRCA1/2 are at very high risk of developing breast and ovarian cancer. Breast conserving therapy is associated with a similar risk of ipsilateral cancer recurrence in BRCA carriers compared with non-c
Autor:
Shulamith Rizel, Michelle Leviov, Debbie M Jakubowski, David B. Geffen, Ora Rosengarten, Mariana Steiner, Steven Shak, Avital Bareket-Samish, Noa Ben-Baruch, Margarita Tokar, Amit Itay, Daniela Katz, Julie Baron, Nicky Liebermann, Salomon M. Stemmer, Lior Soussan-Gutman, Beatrice Uziely, Bella Nisenbaum, Georgeta Fried
Publikováno v:
npj Breast Cancer, Vol 5, Iss 1, Pp 1-6 (2019)
NPJ Breast Cancer
NPJ Breast Cancer
The 21-gene Recurrence Score (RS) assay is a validated prognosticator/predictor of chemotherapy (CT) benefit in early-stage estrogen receptor (ER)-positive breast cancer (BC). Long-term data from real-life clinical practice where treatment was guided
Autor:
Shulamith Rizel, S.M. Stemmer, Tamar Peretz, Ora Rosengarten, Larisa Ryvo, Nicky Liebermann, Georgeta Fried, Christer Svedman, Lior Soussan-Gutman, N Ben Baruch, Avital Bareket-Samish, Bella Nisenbaum, David B. Geffen, Debbie McCullough, Mariana Steiner
Publikováno v:
Cancer Research. 78:P1-07
Background: The 21-gene Recurrence Score (RS) Assay (Oncotype DX®) is a validated prognosticator and predictive of chemotherapy (CT) benefit in patients with hormone receptor (HR)+ human epidermal growth factor receptor 2 (HER2)-negative breast canc
Autor:
Steven Shak, Ora Rosengarten, Shulamith Rizel, Bella Nisenbaum, Christer Svedman, Noa Ben-Baruch, Mariana Steiner, Lior Soussan-Gutman, Salomon M. Stemmer, Georgeta Fried, Nicky Liebermann, David B. Geffen, Tamar Peretz, Debbie McCullough, Kevin Isaacs, Avital Bareket-Samish
Publikováno v:
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
NPJ Breast Cancer
NPJ Breast Cancer
The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative breast cancer. This retrospective analysis of a prospectively designed registry evaluated treatments/outcomes in node-positive breast cancer patients who were Recurrence S
Autor:
David B. Geffen
Publikováno v:
Annals of Oncology. 29:1096-1098
Publikováno v:
Oncology. 97(5)
Background: Recent studies have shown that the peripheral blood pretreatment neutrophil/lymphocyte ratio (NLR) is a prognostic measure in various cancers. The few studies evaluating NLR in glioblastoma multiforme (GBM) patients yielded inconsistent r